Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer
Author(s)
Syed, N
Type
Journal Article
Abstract
The polo-like kinase PLK2 has recently been identified as a potential theranostic marker in the management of chemotherapy sensitive cancers. The methylation status of the PLK2 CpG island varies with sensitivity to paclitaxel and platinum in ovarian cancer cell lines. Importantly, extrapolation of these in vitro data to the clinical setting confirms that the methylation status of the PLK2 CpG island predicts outcomes in patients treated with carboplatin & paclitaxel chemotherapy. A second cell cycle regulator, p57Kip2, is also subject to epigenetic silencing in carboplatin resistance in vitro and in vivo, emphasising that cell cycle regulators are important determinants of sensitivity to chemotherapeutic agents and providing insights into the phenomenon of collateral drug sensitivity in oncology. Understanding the mechanistic basis and identification of robust biomarkers to predict collateral sensitivity may inform optimal use of chemotherapy in patients receiving multiple lines of treatment.
Date Issued
2012-01-28
Date Acceptance
2012-01-26
Citation
Oncotarget, 2012, 3, pp.78-83
ISSN
1949-2553
Publisher
Impact Journals
Start Page
78
End Page
83
Journal / Book Title
Oncotarget
Volume
3
Copyright Statement
© Coley et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0/, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
License URL
Identifier
https://www.oncotarget.com/article/332/text/
Subjects
Science & Technology
Life Sciences & Biomedicine
Oncology
Cell Biology
Polo Like Kinases
Chemotherapy resistance
collateral sensitivity
OVARIAN-CANCER
COLLATERAL SENSITIVITY
RESISTANCE
CELLS
PACLITAXEL
PATHWAYS
PI3K/PTEN/AKT/MTOR
CHEMOSENSITIVITY
RAS/RAF/MEK/ERK
IDENTIFICATION
Animals
Biomarkers, Tumor
Carcinoma
Drug Resistance, Neoplasm
Epigenesis, Genetic
Female
Gene Expression Regulation, Neoplastic
Genes, Tumor Suppressor
Humans
Ovarian Neoplasms
Protein-Serine-Threonine Kinases
Animals
Humans
Carcinoma
Ovarian Neoplasms
Protein-Serine-Threonine Kinases
Epigenesis, Genetic
Gene Expression Regulation, Neoplastic
Drug Resistance, Neoplasm
Genes, Tumor Suppressor
Female
Biomarkers, Tumor
1112 Oncology and Carcinogenesis
Publication Status
Published
Date Publish Online
2012-01-28